Key Points
- CEO Cameron Turtle sold 15,000 shares on Feb. 2 at an average of $32.80 for proceeds of $492,000, leaving him with 657,540 shares (a 2.23% stake reduction); he also sold 15,000 shares on Jan. 2 and Dec. 1, bringing recent insider sales to 45,000 shares.
- SYRE trades around $32 (opened $32.07) with a 52‑week range of $10.91–$35.31 and a $2.49 billion market cap, and analysts hold a consensus "Buy" rating with an average price target of $53.88.
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $32.80, for a total transaction of $492,000.00. Following the completion of the sale, the chief executive officer directly owned 657,540 shares in the company, valued at $21,567,312. This trade represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Cameron Turtle also recently made the following trade(s):
- On Friday, January 2nd, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The shares were sold at an average price of $30.68, for a total value of $460,200.00.
- On Monday, December 1st, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $29.02, for a total value of $435,300.00.
Spyre Therapeutics Stock Performance
Shares of SYRE stock opened at $32.07 on Thursday. The stock has a 50 day moving average price of $32.52 and a 200 day moving average price of $23.76. Spyre Therapeutics, Inc. has a 52-week low of $10.91 and a 52-week high of $35.31. The firm has a market capitalization of $2.49 billion, a P/E ratio of -14.64 and a beta of 3.15.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.53. As a group, sell-side analysts forecast that Spyre Therapeutics, Inc. will post -4.46 EPS for the current year.
Institutional Investors Weigh In On Spyre Therapeutics
Several large investors have recently bought and sold shares of SYRE. Affinity Asset Advisors LLC raised its holdings in Spyre Therapeutics by 26.0% in the 2nd quarter. Affinity Asset Advisors LLC now owns 606,678 shares of the company's stock valued at $9,082,000 after acquiring an additional 125,000 shares during the last quarter. Franklin Resources Inc. raised its holdings in Spyre Therapeutics by 4.6% in the 2nd quarter. Franklin Resources Inc. now owns 795,275 shares of the company's stock valued at $11,905,000 after buying an additional 34,647 shares during the period. Intech Investment Management LLC lifted its holdings in shares of Spyre Therapeutics by 22.1% in the 2nd quarter. Intech Investment Management LLC now owns 24,945 shares of the company's stock worth $373,000 after acquiring an additional 4,517 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Spyre Therapeutics during the third quarter worth $310,000. Finally, AlphaQuest LLC boosted its holdings in Spyre Therapeutics by 1,485.1% during the 3rd quarter. AlphaQuest LLC now owns 66,163 shares of the company's stock valued at $1,109,000 after acquiring an additional 61,989 shares during the period. 80.39% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
SYRE has been the subject of several research analyst reports. Citigroup assumed coverage on shares of Spyre Therapeutics in a research note on Wednesday, December 17th. They set a "buy" rating and a $64.00 price target for the company. Jones Trading upgraded shares of Spyre Therapeutics from a "hold" rating to a "buy" rating and set a $64.00 price target on the stock in a report on Monday, December 1st. Weiss Ratings restated a "sell (e+)" rating on shares of Spyre Therapeutics in a report on Monday, December 29th. Mizuho raised Spyre Therapeutics to a "strong-buy" rating in a research report on Thursday, December 18th. Finally, BTIG Research restated a "buy" rating and set a $70.00 price objective on shares of Spyre Therapeutics in a research note on Friday, January 16th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $53.88.
Read Our Latest Stock Report on SYRE
Spyre Therapeutics Company Profile
(
Get Free Report)
Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.
Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
